ABSTRACT
Introduction
Pulmonary surfactant is a lipoprotein complex, synthesized and secreted by alveolar type II cells. It reduces the surface tension at the lung alveolar airliquid interface and is composed of phospholipids, cholesterol and proteins. Four surfactant associated proteins (SP) have been identified and can be divided into two groups: the hydrophilic proteins SP-A and SP-D, and the hydrophobic proteins SP-B and SP-C (5).
SP-A is a 34-36 kDa protein that facilitates the surface tension lowering properties of surfactant phospholipids in the alveolus, regulates surfactant phospholipid synthesis, secretion, and recycling. It counteracts the inhibitory effects of plasma proteins released during lung injury on surfactant function (24) . SP-A and SP-D are involved in innate immune responses in the lung via their ability to bind various pathogens including viruses, bacteria, fungi, and particulates such as pollen grains and mite allergens (6) .
SP-A is the most abundant of the surfactant proteins (24) . Human SP-A protein is encoded by two genes, SP-A1 and SP-A2, which are 94% identical in nucleotide sequence and 96% identical in amino acid sequence (7, 10, 26) . The primary structure of SP-A protein consists of four domains: an amino-terminal domain, a collagenous domain, a neck domain, and a carbohydrate recognition domain (CRD). In the lung alveolus, human SP-A forms trimers that are thought to be composed of two SP-A1 molecules and one SP-A2 molecule. The native SP-A protein is made up of six SP-A trimers that form a "flower bouquet" structure (23) . Post-translational modifications of SP-A include cleavage of a signal peptide, hydroxylation of proline residues, sulfation, acetylation, and glycosylation with N-linked oligosaccharides (24) . Several proteins have been suggested as a candidate for the cellular SP-A receptor. A 126 kDa protein named C1qRp has been described to binds C1q, mannose binding lectin, and SP-A (17). Another SP-A receptor is a 210 kDa protein present in rat lung and the U937 cell line (4). Binding of SP-A to this receptor is calcium dependent. Polyclonal antibodies against this SP-A receptor block the inhibitory effects of SP-A on phospholipid secretion by alveolar type II cells and block SP-Amediated uptake of bacillus Calmette-Guerin by rat macrophages (25) . A third SP-A receptor identified on rat alveolar type II cells is a ≈200 kDa protein that may be responsible for SP-A-mediated uptake of phosphatidylcholine by alveolar type II cells (13) .
IL-6-type cytokines (IL-6, IL-11, LIF, OSM, CNTF and CT-1) use the common receptor subunit gp130 for signal transduction and as a consequence elicit similar and overlapping physiological responses (8 hematopoiesis, neural differentiation and acute phase reaction (8) . Binding of IL-6 to its receptor (IL-6R, gp80) induces the homo-dimerization of two gp130 molecules which in turn activates the Janus kinase/signal transducer and activator of transcription (Jak/STAT) cascade thereby transducing the signal to IL-6 responsive genes in the nucleus (8, 9) . The STAT activation after stimulation is transient, being maximal after 30 minutes and disappearing after 60-90 minutes (22) .
Human SP-A increases the production of proinflammatory cytokines (TNF-a, interleukins) in rat alveolar macrophages and peripheral blood mononuclear cells (11) . These effects as well as the increase in the expression of cell surface proteins (CD14, CD54, and CD11b) have been observed in a human monocytic/macrophage cell line, THP-1 cells (12) .
In this study we have addressed the question whether there is correlation between increased levels of IL-6 and production of SP-A from A549 lung cell line. To answer this question the cells were stimulated for different time with IL-6 and expression of SP-A was analyzed by Western blot.
Our results suggest correlation between increased levels of IL-6 and decreased production of SP-A.
Materials and Methods
All reagents and chemicals were supplied by Sigma-Aldrich (Sofia, Bulgaria) unless otherwise indicated. Protein ColorBurst Electrophoresis marker was obtained from Sigma. Recombinant human IL-6 was pursed from R&D systems (Sofia, Bulgaria). Antibodies were obtained as follows: rabbit IgG antibody (H-148) against human SP-A from Santa Cruz (Sofia, Bulgaria), HRP-linked anti-rabbit IgG from Enzo Life Science (Sofia, Bulgaria).
Cell culture A549 human lung cells were incubated in DMEM containing 10% Fetal Calf Serum (FCS), streptomycin (100 mg/l) and penicillin (60 mg/l) over night at 37°C and 5% CO 2 . For cell extraction studies, 30,000 cells were plated and grown in 24-well plates to reach 90% confluences and preincubated in DMEM containing 1% FCS overnight. Cells were stimulated for different time (15 min., 30 min., 45 min., 60 min., 90 min.) with 20 ng/ml IL-6 (20, 22) in 1% FCS DMEM. After stimulation cells were incubated for 12h and 24h in 1% FCS DMEM respectively.
Cell lyses and Western blot
Cells were extracted with 200 µl RIPA buffer and a cocktail of protease inhibitors. Lysates containing 6µg proteins were dissolved in reducing sample buffer and separated by 10% SDS-PAGE.
Electrophoretically separated proteins were transferred to Nitrocellulose membrane (AppliChem) by wet western blotting. Non-specific binding was blocked with 10% BSA in TBS (25 mM Tris-HCl pH 7.4, 150 mM NaCl) for 1 hour. Blots were incubated overnight with human anti-SP-A-specific rabbit antibody at 4°C followed by incubation with HRP-conjugated anti-rabbit IgG antibody for 2 hours at room temperature. Bands were detected using Amersham Hyperfilm™ MP (GE Healthcare). X-ray films were scanned and sample signals from the same experiment present on the same blot were quantified with NIH ImageJ 1.42 software.
Results and Discussion
SP-A levels in alveolar surfactant are increased by treatment with cAMP analogs (16, 27) , epidermal growth factor (28), interferon gamma (3), prostaglandins (1), oxygen (2), endotoxin (15) , and b-adrenergic agonists (18) . Expression of SP-A is decreased by insulin (21) and tumor necrosis factor a (TNF-a) (29) . Both inhibitory and stimulatory effects of glucocorticoids on SP-A expression have been reported, with the inhibitory effect observed at higher hormone concentrations (14, 19) .
Since SP-A gene expression is regulated by several growth factors, hormones, and regulatory agents (24) and IL-6 elevation in fetuses with chorioamnionitis promotes fetal lung maturation by inducing SP-A synthesis (20) and thereby decreasing the incidence of Respiratory Distress Syndrome in preterm infants, we investigated correlation between increased levels of IL-6 and production of SP-A from A549 lung cell line. In order to reveal the relationship between IL-6 and SP-A Western blots analyses of extracted cells were performed.
A549 cells originated from pneumocytes type II. These pneumocytes are main producers of pulmonary surfactant and show increased phagosytotic activities. In this study A549 cells were stimulated with 20 ng/ml IL-6 for 0 to 90 min. and time-course of SP-A protein expression was monitored after 12h and 24h in DMEM with 1% FCS, respectively. This time was enough to monitored IL-6 effects on SP-A protein synthesis.
In our experiments two types of controls, without IL-6 activation were used. In control K1 cells were cultivated in 10% FCS (standard cell culturing conditions) while in K2 cells were cultivated in 1% FCS. In K2 the amount of growth factors and cytokines, including IL-6, is ten times smaller than in K1. Growth factors and hormones are presented in FCS, thus K2 control allows only the effect of IL-6, applied on the cells to be identified.
Signal intense in both controls was lower than signals from cells stimulated with IL-6 for 15 min., The differences in the SP-A expression in the cells with and without stimulation with IL-6 were bigger 12h after stimulation in comparison with 24h after stimulation. Probably this is due to the recovery of the cells with the time to the conditions before stimulation.
Our findings of minimal expression of SP-A protein (after 30-45 min of stimulation with IL-6) correlate well with maximal activation of Jak/STAT pathway (30 min. after stimulation with IL-6), reported by (22) . At earlier and later time points more intensive wave of activation of SP-A synthesis was observed ( Fig. 1 and Fig. 2) . The strongest SP-A expression we detected after 90 min of activation with IL-6. According to Thiel et al. at that time STAT3 signal disappears almost completely (22) .
Differences observed between K1 and K2 correlates well with the relationship between amount of IL-6 and SP-A protein expressionhigher levels of IL-6 promotes lower levels of SP-A expression (see above).
IL-6 stimulation was for relatively short time period (0-90 min) and we investigated the amount of SP-A expression after 12h and 24h, the time that should be enough not only for the activation of transcription, but for the translation and posttranslational modifications of SP-A.
Among IL-6-type cytokine target genes that are activated via STATs are APP genes such as Creactive protein, lipopolysaccharide -binding protein and tissue inhibitor of metalloproteinases (TIMP)-1, transcription factors such as Jun B, cFos, interferon regulatory factor (IRF)-1 and CCAAT enhancer binding protein (C}EBP)d, interstitial collagenase, vasoactive intestinal peptide, pro-opiomelanocortin, heat-shock protein hsp90, bcl-x and the IL-6 signal transducer gp130 (8) .
Conclusions
There is no current evidence that SP-A1 and SP-A2 are target genes for STATs. Our results underline the crucial role of IL-6 for SP-A expression. Incubation of A549 cells with IL-6 for different time changes the expression levels of SP-A and there is correlation between increased levels of IL-6 and decreased production of SP-A from A549 lung cell line. Maximal pick of STAT activation corresponds to lower levels of expression of SP-A.
Our results suggest presence of negative correlation between levels of IL-6 and production of SP-A.
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